

Table S1. Multivariate analysis of several clinicopathologic parameters in relation to survival of advanced stage patients (n=87)

Variables (n)	OS		PFS	
	Relative risk (95% CI)	<i>P</i> -value	Relative risk (95% CI)	<i>P</i> -value
<u>Age</u>				
≥60 (61) [vs <60 (26)]	0.45 (0.207-1.002)	0.051	0.653 (0.352-1.210)	0.175
<u>Clear or not</u>				
clear (23) [vs nonclear (64)]	1.394 (0.658-2.951)	0.385	0.699 (0.353-1.384)	0.304
<u>CA125</u>				
≥50 (80) [vs <50 (7)]	2.095 (0.478-9.175)	0.326	2.087 (0.611-7.132)	0.24
<u>Residual tumor</u>				
Present (39) [vs Absent (48)]	2.624 (1.351-5.093)	0.004	1.331 (0.757-2.343)	0.321
<u>REV7 expression</u>				
High (48) [vs Low (39)]	1.364 (0.715-2.604)	0.346	2.094 (1.178-3.720)	0.012

Table S2. Association between REV7 expression and 1-year progression-free survival in patients with advanced stage EOC received platinum-based chemotherapy (n=82)

	n	REV7 low (%)	REV7 high (%)	<i>P</i> -value
progression (+)	31	9 (29.0)	22 (71.0)	} 0.022
progression (-)	51	29(56.9)	22 (43.1)	